Jiaheng Pharmaceuticals

Jiaheng Pharmaceuticals is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the development of innovative small molecule drugs. The company focuses on therapeutic areas with significant unmet needs, including metabolic diseases and oncology. Its lead program, JH-0402, is a highly selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Jiaheng also maintains a robust pipeline of targeted oncology agents, such as JH-0801, which targets specific mutations in the epidermal growth factor receptor. The company leverages its internal R&D capabilities to advance candidates from discovery through clinical validation.